Hunan Nucien Pharmaceutical Co., Ltd. (SHA:688189)
China · Delayed Price · Currency is CNY 9.33
-0.42 (-4.31%)
At close: May 21, 2026
SHA:688189 Revenue
Hunan Nucien Pharmaceutical had revenue of 26.05M CNY in the quarter ending March 31, 2026, a decrease of -35.88%. This brings the company's revenue in the last twelve months to 127.35M, down -18.35% year-over-year. In the year 2025, Hunan Nucien Pharmaceutical had annual revenue of 141.93M, down -46.09%.
Revenue (ttm)
127.35M
Revenue Growth
-18.35%
P/S Ratio
19.97
Revenue / Employee
347.96K
Employees
319
Market Cap
2.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 141.93M | -121.36M | -46.09% |
| Dec 31, 2024 | 263.28M | -456.78M | -63.44% |
| Dec 31, 2023 | 720.06M | 21.24M | 3.04% |
| Dec 31, 2022 | 698.83M | -44.83M | -6.03% |
| Dec 31, 2021 | 743.66M | -285.48M | -27.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Fengyuan Pharmaceutical | 3.75B |
| Guizhou Yibai Pharmaceutical | 1.72B |
| Enwei Pharmaceutical | 879.60M |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD | 843.87M |
| Zhejiang Shengda Bio-Pharm | 830.53M |
| Jiangxi Synergy Pharmaceutical | 826.15M |
| Hainan Huluwa Pharmaceutical Group | 710.14M |
| Chengdu huasun technology group Inc. , LTD. | 527.86M |